文献速递骨软组织肉瘤与黑色素瘤

新辅助病灶内靶向免疫细胞因子(daromun)治疗III期黑色素瘤

Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma.
PubMed 文献 · Ann Oncol · 2025-07-07

这项III期试验评估daromun(L19IL2与L19TNF组合)作为可临床检测的IIIB/C期黑色素瘤新辅助治疗。患者随机接受每周病灶内daromun注射4周后手术或直接手术。结果显示新辅助组无复发生存期显著延长(中位16.7 vs 6.8个月,HR 0.59),远处复发风险降低40%,但≥3级治疗相关不良事件发生率较高(27.1% vs 6.7%)。

要点

  • 新辅助daromun较直接手术显著延长RFS(HR 0.59,P=0.005)。
  • 远处复发风险降低40%(HR 0.60,P=0.029)。
  • ≥3级TRAE在daromun组为27.1%,多为注射部位反应。

核心结论

  • 新辅助daromun在局部晚期黑色素瘤中较直接手术显著延长无复发生存期。
  • daromun组远处复发风险降低40%,治疗相关不良事件短暂且可控。
  • 新辅助daromun是III期黑色素瘤患者的新治疗选择,包括术后局部区域复发和既往辅助治疗者。

研究设计与样本

  • III期随机对照试验,纳入246例可临床检测的IIIB/C期黑色素瘤患者(AJCC第7版)。
  • 患者随机分配至每周病灶内daromun注射(L19IL2 13百万IU和L19TNF 400 μg)4周后手术组或直接手术组。
  • 允许预先使用已批准的辅助药物,主要终点为无复发生存期(RFS)。

主要发现

  • 中位随访21个月,新辅助组(n=122)中位RFS为16.7个月,直接手术组(n=124)为6.8个月(HR 0.59,95%CI 0.41-0.86,P=0.005)。
  • 新辅助组远处复发风险降低40%(HR 0.60,95%CI 0.37-0.95,P=0.029)。
  • ≥3级治疗相关不良事件发生率:单纯手术组6.7%,daromun组27.1%,主要为注射部位反应。
  • 74%患者既往接受过两次或以上手术切除,35%接受过既往全身治疗。

临床怎么用

  • 对于可临床检测的IIIB/C期黑色素瘤患者,可考虑新辅助daromun治疗后手术。
  • 治疗相关不良事件主要为注射部位反应,短暂且可控,需监测≥3级不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This phase III trial assessed daromun, a combination of two fibronectin-targeting immunocytokines (L19IL2 and L19TNF), as a neoadjuvant treatment for patients with clinically detectable stage IIIB/C melanoma [American Joint Committee on Cancer (AJCC) version 7]. PATIENTS AND METHODS: Patients were randomized to weekly intralesional daromun administrations (13 million IU of L19IL2 and 400 μg of L19TNF) for 4 weeks followed by surgery, or upfront surgery. Pretreatment with approved adjuvant agents was allowed. The primary endpoint was recurrence-free survival (RFS): events were disease recurrence or death from any cause after complete surgical tumor resection (ClinicalTrials.gov NCT02938299). RESULTS: A total of 246 patients were randomized and included in the intention-to-treat analysis: 74% had undergone two or more prior surgical resections and 35% had received prior systemic therapy. At a median follow-up of 21 months, the neoadjuvant group (n = 122) had a significantly longer RFS than the upfront surgery group (n = 124), with a median RFS of 16.7 months and 6.8 months, respectively [hazard ratio (HR) 0.59, 95% confidence interval (CI 0.41-0.86), P = 0.005, log-rank test]. The risk of distant recurrence was reduced by 40% in the neoadjuvant arm (HR 0.60, 95% CI 0.37-0.95, P = 0.029). Grade ≥3 treatment-related adverse events (TRAEs) were 6.7% in the surgery-alone arm and 27.1% in the daromun arm, mostly injection site reactions. CONCLUSIONS: Neoadjuvant daromun resulted in a significantly longer RFS than upfront surgery in patients with locally advanced melanoma. TRAEs were transient and manageable. Neoadjuvant daromun is a new therapeutic option for patients with stage III melanoma, including those with locoregional recurrence after surgery and previous adjuvant therapy.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Kähler KC, Hassel JC, Ziemer M, et al. Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma. Ann Oncol. 2025. PMID: 40633690. doi:10.1016/j.annonc.2025.06.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。